Telix Achieves FY 2025 Guidance with US$804M (A$1.2B) Revenue, Accelerates Growth with Gozellix Launch
Telix provides an update on its commercial and operational performance for the quarter ended 31 December 2025 (Q4 2025).
Chinese NMPA Accepts New Drug Application for Illuccix for Prostate Cancer Imaging
Telix today announces that the Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has accepted the filing of a New Drug Application (NDA) for TLX591-Px (Illuccix®, Kit for the preparation of 68Ga-PSMA-11), Telix’s lead prostate cancer imaging agent.
First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study
Telix today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Biopsy of the Prostate Avoidance Stratification Study), Phase 3 trial to evaluate the use of Telix’s commercial PSMA-PET imaging agents, Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) and Gozellix® (kit for the preparation of gallium Ga 68 gozetotide injection) in the initial prostate cancer diagnosis setting. The dose was administered under the supervision of Dr. Brian Mazzarella at Urology Austin and supplied by RLS Radiopharmacies.
Presentation to J.P. Morgan Healthcare Conference
Telix is pleased to provide a copy of the presentation that will be delivered by Dr. Christian Behrenbruch, Managing Director and Group CEO at the 44th Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA (U.S.).
ZIRDOSE-CP Study of TLX250-CDx published in EJNMMI Research: Confirms Favorable Safety and Tolerability Profile in Chinese patients
Telix today announces that final results from the ZIRDOSE-CP Phase 1 study of TLX250-CDx (Zircaix®, 89Zr-girentuximab) PET imaging in Chinese patients with suspected clear cell renal cell carcinoma (ccRCC) have been published in the European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI) Research.
Telix to Present Pipeline and Commercial Portfolio Overview at J.P. Morgan Healthcare Conference
Telix today advises that Dr. Christian Behrenbruch, Managing Director and Group CEO, will be presenting at the 44th Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA (U.S.).
Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions
Telix today provides a precision medicine portfolio update in relation to
ProstACT Global Study: Status
Telix today provides an update to confirm the current status of the ProstACT Global Phase 3 study of its lead prostate cancer therapy candidate TLX591 (lutetium (177Lu) rosopatamab tetraxetan) in patients with metastatic castration resistant prostate cancer (mCRPC). This announcement is provided in response to inaccurate information in market circulation.
Telix and Varian Announce Strategic Theranostics-EBRT Clinical Collaboration
Telix today announces a strategic clinical collaboration with Varian, a Siemens Healthineers company and global leader in radiation oncology, to develop novel clinical applications that combine Telix’s theranostic products and external beam radiation therapy (EBRT).
ProstACT Global Phase 3 Update: First Patient Dosed in Randomized Treatment Expansion, Part 1 Readout Plans Confirmed
Telix today announces that the first patient has been dosed in Part 2 (randomized treatment expansion) of its ProstACT Global Phase 3 study evaluating its lead prostate cancer therapy candidate TLX591 (lutetium (177Lu) rosopatamab tetraxetan) in patients with metastatic castration resistant prostate cancer (mCRPC). The patient was dosed at the Australian Prostate Centre (APC) in Melbourne, Australia.